BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27167671)

  • 21. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes.
    Morelli M; Scumaci D; Di Cello A; Venturella R; Donato G; Faniello MC; Quaresima B; Cuda G; Zullo F; Costanzo F
    Int J Gynecol Cancer; 2014 May; 24(4):649-58. PubMed ID: 24614826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
    Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
    Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
    Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
    Macwhinnie N; Monaghan H
    Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
    Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic value of combined detection of HNF-1β and Napsin A in the diagnosis of ovarian clear cell carcinoma].
    Wang J; Li Q; Cheng X; Xiong K; Qi Q; Huang W
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):874-8. PubMed ID: 26888504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium.
    Garg K; Soslow RA
    Adv Anat Pathol; 2012 Jan; 19(1):1-10. PubMed ID: 22156830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
    Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
    Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
    Zhang L; Liu Y; Hao S; Woda BA; Lu D
    Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.